RecruitingNCT07338370

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Sponsor

Ain Shams University

Enrollment

34 participants

Start Date

Jan 1, 2026

Study Type

OBSERVATIONAL

Conditions

Neonatal Prematurity Patent Ductus Arteriosus in Preterm Infants Prostaglandins

Summary

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

Eligibility

Min Age: 1 DayMax Age: 7 Days

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ibuprofen (Brufen®) for people with neonatal prematurity, patent ductus arteriosus in preterm infants, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Day to 7 Days.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIbuprofen (Brufen®)

Group1will receive anti-PGE; Ibuprofen (IBU) (brufen)® syrup will be given for 3 days enterally either orally or via a gastric tube with an initial dose of 10mg/kg/day, followed by 5mg/kg/day for the next 2 days. Group 2 will be observed and follow up echocardiography and PGE2 level will be followed up 3 days after treatment or follow up in both groups.

Locations(1)

Faculty of Medicine, Ain Shams, University

Cairo, Abbasia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07338370